osimertinib,gefitinib
astrazeneca
['gefitinib', 'sclc', 'lcsm,(-blcsm)', 'nsclc', 'osimertinib']
#asco23 egfr symposium ph iii trial jcog1404 of cis/pem + egfr tki in 1l egfrmt nsclc: - initially designed with gefitinib, study amended to osimertinib during the study
- marginal pfs benefit with tki+chemo combo, no os benefit #lcsm 
Professor of Medical Oncology @CancerCentreIre | Thoracic Oncologist | Immunotherapy & Immune toxicity | Adjunct faculty Johns Hopkins University